Mixed neuroendocrine non-neuroendocrine neoplasms in gastroenteropancreatic tract

Table 3 Adjuvant treatment in mixed neuroendocrine non-neuroendocrine neoplasms

Ref.	Number	Location	Chemotherapy scheme	Result
Wen et al[68], 2020	n = 67	Biliary tract	Adjuvant CT-RT after R0 (n = 22) vs only surgery (n = 29); platinum and fluoropyrimidine regimens	OS, P = 0.076
Nießen et al[69], 2021	n = 13	Pancreatic	Adjuvant after surgery (n = 11); gemcitabine = 9; platinum-etoposide = 2	At 17-month follow-up, 2 patients were alive with no evidence of disease, 2 were alive with disease and 9 had died from the disease. 2 patients who had received NE regimens were alive
Zheng et al[70], 2021	n = 777	Gastric	Adjuvant after surgery (n = 198); unspecified regimen	DFS, P = 0.051
Watanabe et al[43], 2016	-	CCR	Adjuvant after surgery (MANEC n = 15 vs ADC n = 23); platinum and fluoropyrimidine regimens	DFS, P = 0.268; there were no differences between them
Wang et al[40], 2021	-	Gallbladder	Adjuvant after surgery (n = 15) vs only surgery (n = 15); capecitabine	DFS, P = 0.916

CT-RT: Chemotherapy and radiotherapy; R0: Adequate margins free of neoplasia; OS: Overall survival; NE: Neuroendocrine; DFS: Disease free survival; CCR: Colorectal cancer; MANEC: Mixed adeno-neuroendocrine carcinomas; ADC: Adenocarcinoma.